NurExone Biologic (NRX) Price & Analysis

13 Followers

NRX Stock Chart & Stats

C$0.63

Market closed

C$0.63

Day’s Range― - ―

52-Week RangeC$0.51 - C$1.14

Previous CloseN/A

VolumeN/A

Average Volume (3M)93.90K

Market Cap

C$40.37M

Enterprise ValueC$51.62M

Total Cash (Recent Filing)N/A

Total Debt (Recent Filing)N/A

Price to Earnings (P/E)―

Beta0.02

Next Earnings

Sep 02, 2026

EPS Estimate

-0.03

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding73,395,850

10 Day Avg. Volume101,595

30 Day Avg. Volume93,898

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusModerate Buy

Number of Analyst Covering0

EPS Forecast (FY)-0.06

Revenue Forecast (FY)N/A

NurExone Biologic News

NurExone’s Exo-Top Signs LOI With BioXtek for U.S. Exosome Manufacturing Push

NurExone Biologic ( ($TSE:NRX) ) has provided an update. NurExone Biologic’s U.S. subsidiary Exo-Top has signed a non-binding...

3M ago

NurExone Wins BOLD Healthcare Award and Hires IBN to Boost Investor Visibility

An update from NurExone Biologic ( ($TSE:NRX) ) is now available. NurExone Biologic, a developer of exosome-based therapies...

3M ago

NurExone Bolsters U.S. Exosome Manufacturing With Exo‑Top Sublicense

NurExone Biologic ( ($TSE:NRX) ) just unveiled an update. NurExone has executed an internal sublicense granting its U.S....

3M ago

NRX Upcoming Earnings Report: What to Expect?

Nurexone Biologic Inc. (NRX) is scheduled to report 4th quarter earnings on 03/26/2026. Regarding Q4 estimates, Wall Street...

3M ago

NurExone Bolsters European Push and Balance Sheet With Strategic Hire and C$880K Financing

NurExone Biologic ( ($TSE:NRX) ) has provided an announcement. NurExone has strengthened its European scientific capabilities by engaging...

4M ago

NurExone to Spotlight Exosome Platform at Key 2026 Conferences as Executive Departs

An announcement from NurExone Biologic ( ($TSE:NRX) ) is now available. NurExone Biologic plans to highlight its exosome-based...

4M ago

NurExone Bolsters Exosome Manufacturing Consistency Ahead of Clinical Push

The latest update is out from NurExone Biologic ( ($TSE:NRX) ). NurExone Biologic reported independent proteomic analysis from...

5M ago

NurExone Adds Healthcare Heavyweight Eyal Gabbai to Board as It Advances Exosome Platform

NurExone Biologic ( ($TSE:NRX) ) has provided an announcement. NurExone Biologic has appointed Eyal Gabbai to its board...

5M ago

NurExone Exosomes Show Strong Anti-Inflammatory Effect, Outperform Commercial Rival in Lab Tests

The latest announcement is out from NurExone Biologic ( ($TSE:NRX) ). NurExone Biologic reported new laboratory data showing...

6M ago

NurExone Advances ExoPTEN Manufacturing for Future Clinical Trials

NurExone Biologic ( ($TSE:NRX) ) has issued an announcement. NurExone Biologic Inc. has announced progress in its clinical-readiness...

7M ago

NRX FAQ

What was NurExone Biologic’s price range in the past 12 months?

NurExone Biologic lowest stock price was C$0.51 and its highest was C$1.14 in the past 12 months.

What is NurExone Biologic’s market cap?

NurExone Biologic’s market cap is C$40.37M.

When is NurExone Biologic’s upcoming earnings report date?

NurExone Biologic’s upcoming earnings report date is Sep 02, 2026 which is in 62 days.

How were NurExone Biologic’s earnings last quarter?

Currently, no data Available

Is NurExone Biologic overvalued?

According to Wall Street analysts NurExone Biologic’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does NurExone Biologic pay dividends?

NurExone Biologic does not currently pay dividends.

What is NurExone Biologic’s EPS estimate?

NurExone Biologic’s EPS estimate is -0.03.

How many shares outstanding does NurExone Biologic have?

NurExone Biologic has 73,395,850 shares outstanding.

What happened to NurExone Biologic’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of NurExone Biologic?

Currently, no hedge funds are holding shares in TSE:NRX

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

NurExone Biologic

NurExone Biologic Inc., a pharmaceutical technology company, develops a platform for biologically guided exosome-based therapies for the treatment of central nervous system injuries. Its lead product, ExoPTEN, has demonstrated strong preclinical data supporting clinical potential in treating acute spinal cord and optic nerve injury. The company was founded on June 27, 2011 and is headquartered in Toronto, Canada.